Reactive Arthritis News

While no biosimilars indicated for rheumatic diseases in the U.S. have been approved by the FDA, reader interest in the topic has been high as results from clinical trials and other clinical data are revealed.

In agreement with the FDA’s recent draft guidance on nonproprietary naming of biological products, six physician groups collectively sent a letter to CMS Acting Administrator Andrew Slavitt on Tuesday urging CMS to adopt unique billing codes for biosimilars, according to a press release.

The American College of Rheumatology has announced its support for the recently released FDA draft guidance regarding a methodology for nonproprietary naming of biologic and biosimilar therapies.

The FDA announced the availability of a draft guidance describing its proposal on the nonproprietary naming of biological products.

Musculoskeletal ultrasound imaging may be a complementary tool in the assessment and ongoing monitoring of symptoms in children with reactive arthritis, according to recently presented data.

The Coalition of State Rheumatology Organizations has released the results of a survey of rheumatologists showing that most rheumatologists look forward to the availability of biosimilars, but also that they want the FDA to take specific regulatory steps to ensure patient safety, according to a press release.

According to data presented at the European League Against Rheumatism Annual European Congress of Rheumatology, temporary work disability may be reduced with early intervention for musculoskeletal diseases.

New genetic variants and polymorphisms were identified using next-generation sequencing in patients with autoinflammatory diseases, according to study findings presented at the European League Against Rheumatism Annual European Congress of Rheumatology.

Physicians were more likely to score patient fatigue lower than patient-reported scores among patients with rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus and fibromyalgia, according to research presented at the European League Against Rheumatism Annual European Congress of Rheumatology.

Only a small number of patients with rheumatic diseases said fatigue-related communication with a rheumatologist was not important; however, less than half of patients studied were satisfied with actual communication, and more than three-quarters of patients reported that the fatigue-related communication was initiated by the patient, according to survey results presented at the European League Against Rheumatism Annual European Congress of Rheumatology.